Table 1 Baseline characteristics of the patients enrolled in this study
Characteristics | Number of patients N (%) |
|---|---|
Median age (years, range) | 59 (39–91) |
Sex | |
 Men | 33 (56.9) |
 Female | 25 (43.1) |
ECOG performance status | |
 1 | 56 (96.6) |
 2 | 2 (3.4) |
Disease status | |
 Recurrent | 14 (24.1) |
 Metastatic | 44 (75.9) |
Number of metastatic sites | |
 ≤2 | 25 (43.1) |
 2< | 33 (56.9) |
Number of prior regimen for advanced disease | |
 1 | 5 (8.6) |
 2 | 46 (79.3) |
 3 | 6 (10.3) |
 4 | 1 (1.7) |
Previous anti-VEGF treatment | |
 Bevacizumab | 18 (31.0) |
BRAF status (V600E) | |
 Mutant | 3 (5.1) |
 Wild type | 51 (88.1) |
 Unknown | 4 (6.8) |
PIK3CA status | |
 Mutant | 0 (0.0) |
 Wildtype | 50 (86.2) |
 Unknown | 8 (13.8) |